Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates
Zacks Investment Research | Feb 18, 2020 09:21PM ET
It was a ho-hum week for the biotech sector with Incyte (NASDAQ:INCY) coming out with strong results for the fourth quarter, and pipeline and regulatory updates from a few small biotech players.
Recap of the Week’s Most Important Stories:
Strong Q4 Results From Incyte: Incyte Corporation reported better-than-expected results for the fourth quarter of 2019, wherein both earnings and sales beat expectations. Demand for Jakafi in all three approved indications (polycythemiavera, myelofibrosis and the recent label expansion in acute graft-versus-host disease) continues to grow. The guidance for 2020 was encouraging as well.
Bellerophon Soars on Positive Data: Shares of clinical-stage biotherapeutics company, Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) , soared after it announced positive top-line data from a recently completed acute, intra-patient, dose-escalation, hemodynamics study (PHPF-002) of INOpulse for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF). The top-line results from PHPF-002 demonstrated that acute treatment with INOpulse provided statistically and clinically significant improvements in hemodynamic parameters.
Horizon Gets FDA Approval for New Procysbi Dosage: Horizon Therapeutics plc (NASDAQ:HZNP) announced today that the FDA has approved Pprocysbi (cysteamine bitartrate) delayed-release oral granules in packets for adults and children one year of age or above living with nephropathic cystinosis. The new dosage form provides another option for people living with cystinosis, in addition to the currently available Procysbi capsules.
Horizon carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
FDA Accepts Epizyme’s Application of Tazverik: The FDA has accepted for filing Epizyme’s (NASDAQ:EPZM) New Drug Application (NDA) for the accelerated approval of Tazverik (tazemetostat) for patients with relapsed or refractory follicular lymphoma (FL), who have received at least two prior lines of systemic therapy. The FDA granted Priority Review and has set a target action date of Jun 18, 2020. Epizyme’s sNDA submission is based primarily on updated phase II efficacy and safety data for Tazverik in this patient population.
We note that Tazverik is already indicated for the treatment of adults and pediatric patients aged 16 years or above with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Seattle Genetics’ Application for Tucatinib Accepted: The FDA has accepted for priority review Seattle Genetics’ (NASDAQ:SGEN) New Drug Application (NDA) for experimental drug, tucatinib. The company is seeking FDA approval of tucatinib in combination with trastuzumab and capecitabine for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least three prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting. The FDA has set a target action date of Aug 20, 2020. Tucatinib is an oral, small-molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2.
Performance
Get The News You Want
Medical - Biomedical and Genetics Industry 5YR % Return
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.